Global Non-Invasive Prenatal Testing (NIPT) Market Set for Rapid Growth, to Reach Around USD 1,086.36 Million by 2022

12-Dec-2017 | Zion Market Research

Zion Market Research has published a new report titled “Non-Invasive Prenatal Testing (NIPT) Market by Test Type (Panel 1, Panel 2 and Panel 3) and End-users (Hospitals, Diagnostic Centers, and Maternity Clinics): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2016 - 2022”. According to the report, global non-invasive prenatal testing (NIPT) market was valued at approximately USD 590.32 million in 2016 and is expected to generate revenue of around USD 1,086.36 million by end of 2022, growing at a CAGR of around 10.7% between 2017 and 2022.

Non-invasive prenatal testing is an advanced technology that helps determine fetal chromosomal anomalies by analyzing the fetus cell-free DNA. As the invasive procedures have a higher risk quotient, including the risk of fetal loss, most healthcare professionals prefer non-invasive techniques. NIPTs are new genetic tests that use cell-free circulating fetal DNA in the maternal serum to screen for more common fetal aneuploidies, such as trisomy 21, trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome), and monosomy X (Turner syndrome). With increased patient access to healthcare information as well as advertising, the NIPT market is anticipated to have a positive outlook in the coming years.

Request Sample Request Customization Buy Now

Browse the full " Non-Invasive Prenatal Testing (NIPT) Market by Test Type (Panel 1, Panel 2 and Panel 3) and End-users (Hospitals, Diagnostic Centers, and Maternity Clinics): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2016 - 2022" report at

Advantages offered by NIPT such as non-invasiveness, high accuracy, and early detection, raising awareness, increasing market penetration in highly untapped countries in Asia and Latin America and continuous increase in average maternal age are the major factors expected to drive the growth of the global NIPT market during the forecast period. However, the market is also facing significant ethical and regulatory hurdles associated with the implementation of NIPT because of the belief that it is likely to increase the incidence of abortions. Therefore, various professional organizations such as the American College of Obstetricians and Gynecologists (ACOG), the International Society for Prenatal Diagnosis, the Japan Society of Obstetrics and Gynecology, and genetic counselors across the world have set up guidelines that limit the use of non-invasive prenatal testing only to pregnant women at high risk of chromosomal aneuploidies.


The non-invasive prenatal testing market is segmented on the basis of test type into panel 1, panel 2 and panel 3 test. Panel 1 segment is expected to grow at fastest rate in the global market over the forecast period. Hospitals, diagnostic centers, and maternity clinics are the key end-users of the global non-invasive prenatal testing market. The hospital's segment dominated the market in terms of revenue in 2016. 

North America, Europe, Asia-Pacific, Latin America and Middle East & Africa are key regional segments of the global non-invasive prenatal testing market. North America held the largest share of the global NIPT market in terms of revenue. Major players domiciled in the U.S. and relatively high awareness levels about NIPT in North America are the key factors attributed to the region’s leadership position. In Europe, market growth largely depends upon increasing penetration of these U.S.-based test developers and increase in acceptance of these tests. Japan, Australia, China, and India represent high growth potential markets in Asia-Pacific. The NIPT market in China is dominated by two local players BGI Diagnostics and Berry Genomics. In addition, the recent CFDA approval for Bambini Test would propel the growth of the market in this region.

Some of the key players in the non-invasive prenatal testing market include Ariosa Diagnostics, Inc., Berry Genomics Co., Ltd, BGI Diagnostics, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom Laboratories, and Quest Diagnostics, Inc. The market is saturated with few players operating in the NIPT space and these companies are expected to compete on the grounds of cost and functionality. Product differentiation, new product launches and merger and acquisition are some of the strategies adopted by these industry participants. 

This report segments the global non-invasive prenatal testing market as follows:

Global Non-Invasive Prenatal Testing (NIPT) Market: Test Type Segment Analysis

  • Panel 1
  • Panel 2
  • Panel 3

Global Non-Invasive Prenatal Testing (NIPT) Market: End-user Segment Analysis

  • Hospitals
  • Diagnostic Centers
  • Maternity Clinics

Global Non-Invasive Prenatal Testing (NIPT) Market: Regional Segment Analysis

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Browse New Press Release:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States.

Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Download Brochure
Latest Published Reports

View All Published Reports